Federal Register Notice: FDA has submitted a proposed collection of information entitled, “Study to Measure the Compliance of Prescribers With the Contraindication of the Use of Triptans in Migraine Headache Patients With Vascular Disease” to the Office of Management and Budget. To view this notice, click here.
